Order Article Reprints

Wieczorek A, Manzitti C, Garaventa A, Gray J, Papadakis V, Valteau-Couanet D, Zachwieja K, Poetschger U, Pribill I, Fiedler S, et al. Clinical Phenotype and Management of Severe Neurotoxicity Observed in Patients with Neuroblastoma Treated with Dinutuximab Beta in Clinical Trials. Cancers. 2022; 14(8):1919. https://doi.org/10.3390/cancers14081919

Wieczorek, Aleksandra, Carla Manzitti, Alberto Garaventa, Juliet Gray, Vassilios Papadakis, Dominique Valteau-Couanet, Katarzyna Zachwieja, Ulrike Poetschger, Ingrid Pribill, Stefan Fiedler, and et al. 2022. "Clinical Phenotype and Management of Severe Neurotoxicity Observed in Patients with Neuroblastoma Treated with Dinutuximab Beta in Clinical Trials" Cancers 14, no. 8: 1919. https://doi.org/10.3390/cancers14081919

Wieczorek, A., Manzitti, C., Garaventa, A., Gray, J., Papadakis, V., Valteau-Couanet, D., Zachwieja, K., Poetschger, U., Pribill, I., Fiedler, S., Ladenstein, R., & Lode, H. N. (2022). Clinical Phenotype and Management of Severe Neurotoxicity Observed in Patients with Neuroblastoma Treated with Dinutuximab Beta in Clinical Trials. Cancers, 14(8), 1919. https://doi.org/10.3390/cancers14081919